新型复合病理风险分层系统用于手术切除的人乳头瘤病毒相关口咽癌的建立与评估
这项回顾性队列研究利用美国国家癌症数据库纳入2010年1月1日至2013年12月31日期间接受 upfront 手术和颈淋巴结清扫的15324例非转移性头颈部鳞状细胞癌患者,比较传统病理风险分层对HPV+口咽癌和HPV无关头颈部鳞癌的生存区分度,并推导出新型复合病理风险分层系统。传统分层在HPV+口咽癌的区分度指数为0.58,新系统提高至0.67;新系统低危组接受辅助放疗与生存改善无关,而中危和高危组接受辅助放疗与生存改善相关。
要点
- 传统病理风险分层对HPV+口咽癌生存区分度差,C指数仅0.58。
- 新复合病理风险分层系统将HPV+口咽癌C指数提高至0.67。
- 新系统低危组辅助放疗与生存改善无关,中危和高危组则相关。
核心结论
- 传统病理风险分层对HPV+口咽癌生存区分度差,将许多预后极好患者归为高危。
- 推导的新型复合病理风险分层系统可能改善HPV+口咽癌的生存区分度。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库识别15324例2010年1月1日至2013年12月31日诊断的非转移性头颈部鳞状细胞癌患者,均接受 upfront 手术和颈淋巴结清扫,分析时间为2018年7月1日至2019年1月31日。
主要发现
- 传统病理风险分层下,HPV无关头颈部鳞癌低、中、高危组5年总生存率分别为76.2%、54.5%、40.9%,HPV+口咽癌分别为93.2%、88.9%、83.7%。
- HPV无关头颈部鳞癌的C指数为0.68,HPV+口咽癌的C指数为0.58。
- 新复合风险分层系统纳入病理不良特征的复合数量,HPV+口咽癌C指数提高至0.67。
- 新系统低危组接受辅助放疗与生存改善无关,中危和高危组接受辅助放疗与生存改善相关。
关键数值与推荐
- 传统病理风险分层:HPV无关头颈部鳞癌低危5年总生存率76.2%、中危54.5%、高危40.9%;HPV+口咽癌低危93.2%、中危88.9%、高危83.7%。
- C指数:传统分层HPV无关头颈部鳞癌0.68,HPV+口咽癌0.58;新系统HPV+口咽癌0.67。
- 新系统低危组辅助放疗与生存改善无关,中危和高危组辅助放疗与生存改善相关。
临床怎么用
- 作者推导的新型复合病理风险分层系统可能改善HPV+口咽癌的生存区分度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Human papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) is a distinct form of head and neck squamous cell carcinoma (HNSCC) with its own American Joint Committee on Cancer staging system. However, pathologic risk stratification for HPV+ OPSCC largely remains based on the experience with HPV-unassociated HNSCC. OBJECTIVE: To compare the survival discrimination of traditional pathologic risk stratification for both HPV+ OPSCC and HPV-unassociated HNSCC and derive a novel pathologic risk stratification system for HPV+ OPSCC with improved survival discrimination. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, we used the National Cancer Database to identify 15 324 patients diagnosed with nonmetastatic HNSCC between January 1, 2010, and December 31, 2013, who were treated with upfront surgery and neck dissection. We compared traditional pathologic risk stratification for HPV+ OPSCC and HPV-unassociated HNSCC and then derived a novel pathologic risk stratification system. Analyses were performed from July 1, 2018, to January 31, 2019. EXPOSURES: Definitive primary surgical resection and neck dissection. MAIN OUTCOMES AND MEASURES: Survival discrimination of pathologic risk stratification systems measured with concordance indices. RESULTS: This retrospective cohort study included 15 324 patients (10 779 men and 4545 women; mean [SD] age, 59.9 [11.8] years) with surgically treated nonmetastatic HNSCC. Separation of survival curves for HPV-unassociated HNSCC using traditional pathologic risk stratification (5-year overall survival for the low-, intermediate-, and high-risk groups) were 76.2%, 54.5%, and 40.9%, respectively. Separation curves for HPV+ OPSCC were 93.2%, 88.9%, and 83.7%, respectively. Human papillomavirus-unassociated HNSCC had a concordance index of 0.68, whereas HPV+ OPSCC had a concordance index of 0.58. A novel risk stratification system for HPV+ OPSCC that more closely fits actual survival rates for HPV+ OPSCC was derived. The system incorporated the composite number of pathologic adverse features. This composite risk stratification system was associated with an improved concordance index of 0.67 for HPV+ OPSCC. Adjuvant treatment with radiation was not associated with improved survival for patients categorized as low risk according to the new risk stratification system, but this treatment was associated with improved survival for patients in the intermediate- and high-risk groups. CONCLUSIONS AND RELEVANCE: Traditional pathologic risk stratification shows poor survival discrimination for HPV+ OPSCC and classifies many patients with an excellent prognosis as high risk. We derived a novel composite pathologic risk stratification system for HPV+ OPSCC that may be associated with improved survival discrimination.
引用
- Cramer JD, Dundar Y, Hotaling J, et al. Development and Assessment of a Novel Composite Pathologic Risk Stratification for Surgically Resected Human Papillomavirus-Associated Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31042786. doi:10.1001/jamaoto.2019.0820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。